Cost Effectiveness, Quality-Adjusted Life-Years and Supportive Care

This publication has 17 references indexed in Scilit:

• What are cancer patients willing to pay for prophylactic epoetin alfa?
  Cancer, 1998
• The application of sample selection models to outcomes research: the case of evaluating the effects of antidepressant therapy on resource utilization
  Statistics in Medicine, 1998
• Comment: Cost Comparison of Recombinant Human Erythropoietin and Blood Transfusion in Cancer Chemotherapy-Induced Anemia
  Annals of Pharmacotherapy, 1997
• Pharmacoeconomics: State of the Art in 1997
  Annual Review of Public Health, 1997
• Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group.
  Journal of Clinical Oncology, 1997
• Accounting for future costs in medical cost-effectiveness analysis
  Journal of Health Economics, 1997
• Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system
  Journal of Pain and Symptom Management, 1997
• Cost Comparison of Recombinant Human Erythropoietin and Blood Transfusion in Cancer Chemotherapy-Induced Anemia
  Annals of Pharmacotherapy, 1997
• Transfusion requirements, risks, and costs for patients with malignancy
  Transfusion, 1995
• Healthy-years Equivalents versus Quality-adjusted Life Years
  Medical Decision Making, 1993